Stability of PreservCyt® for Hybrid Capture® (HC II) HPV test

J. Sailors, R. Gander, M. H. Saboorian, P. Berkley, B. Foster, R. Ashfaq

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The Food and Drug Administration (FDA) has approved the Hybrid Capture® II (HC II) assay to test for the presence of high-risk types of human papilloma virus (HPV) DNA using specimens in PreservCyt® fixative for up to 21 days after collection. The ability of HC II to determine the presence of HPV DNA in actual patient samples after longer periods of storage has not been shown. To determine if specimens older than 21 days can yield useful results, 207 patient specimens that had been tested for HPV DNA by HC II (primary test) were tested again after a significant period of storage ranging from approximately 2.5 to 13.5 mo (retest). The results of the primary test and the retest agreed in 86% of the cases. The high level of agreement in the results suggests that the presence of high-risk types of HPV DNA can be determined from actual cervical cytology material in PreservCyt® with the HC II assay for at least 3 mo after specimen collection.

Original languageEnglish (US)
Pages (from-to)260-263
Number of pages4
JournalDiagnostic Cytopathology
Volume32
Issue number5
DOIs
StatePublished - May 2005

Fingerprint

Papillomaviridae
DNA
Specimen Handling
Fixatives
United States Food and Drug Administration
Cell Biology

Keywords

  • Cervical cytology
  • Human papilloma virus
  • Hybrid Capture®
  • Pap smear
  • PreservCyt®
  • Reproducibility

ASJC Scopus subject areas

  • Anatomy

Cite this

Stability of PreservCyt® for Hybrid Capture® (HC II) HPV test. / Sailors, J.; Gander, R.; Saboorian, M. H.; Berkley, P.; Foster, B.; Ashfaq, R.

In: Diagnostic Cytopathology, Vol. 32, No. 5, 05.2005, p. 260-263.

Research output: Contribution to journalArticle

Sailors, J. ; Gander, R. ; Saboorian, M. H. ; Berkley, P. ; Foster, B. ; Ashfaq, R. / Stability of PreservCyt® for Hybrid Capture® (HC II) HPV test. In: Diagnostic Cytopathology. 2005 ; Vol. 32, No. 5. pp. 260-263.
@article{1b834549114b4ed8a64bc096973042c0,
title = "Stability of PreservCyt{\circledR} for Hybrid Capture{\circledR} (HC II) HPV test",
abstract = "The Food and Drug Administration (FDA) has approved the Hybrid Capture{\circledR} II (HC II) assay to test for the presence of high-risk types of human papilloma virus (HPV) DNA using specimens in PreservCyt{\circledR} fixative for up to 21 days after collection. The ability of HC II to determine the presence of HPV DNA in actual patient samples after longer periods of storage has not been shown. To determine if specimens older than 21 days can yield useful results, 207 patient specimens that had been tested for HPV DNA by HC II (primary test) were tested again after a significant period of storage ranging from approximately 2.5 to 13.5 mo (retest). The results of the primary test and the retest agreed in 86{\%} of the cases. The high level of agreement in the results suggests that the presence of high-risk types of HPV DNA can be determined from actual cervical cytology material in PreservCyt{\circledR} with the HC II assay for at least 3 mo after specimen collection.",
keywords = "Cervical cytology, Human papilloma virus, Hybrid Capture{\circledR}, Pap smear, PreservCyt{\circledR}, Reproducibility",
author = "J. Sailors and R. Gander and Saboorian, {M. H.} and P. Berkley and B. Foster and R. Ashfaq",
year = "2005",
month = "5",
doi = "10.1002/dc.20232",
language = "English (US)",
volume = "32",
pages = "260--263",
journal = "Diagnostic Cytopathology",
issn = "8755-1039",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Stability of PreservCyt® for Hybrid Capture® (HC II) HPV test

AU - Sailors, J.

AU - Gander, R.

AU - Saboorian, M. H.

AU - Berkley, P.

AU - Foster, B.

AU - Ashfaq, R.

PY - 2005/5

Y1 - 2005/5

N2 - The Food and Drug Administration (FDA) has approved the Hybrid Capture® II (HC II) assay to test for the presence of high-risk types of human papilloma virus (HPV) DNA using specimens in PreservCyt® fixative for up to 21 days after collection. The ability of HC II to determine the presence of HPV DNA in actual patient samples after longer periods of storage has not been shown. To determine if specimens older than 21 days can yield useful results, 207 patient specimens that had been tested for HPV DNA by HC II (primary test) were tested again after a significant period of storage ranging from approximately 2.5 to 13.5 mo (retest). The results of the primary test and the retest agreed in 86% of the cases. The high level of agreement in the results suggests that the presence of high-risk types of HPV DNA can be determined from actual cervical cytology material in PreservCyt® with the HC II assay for at least 3 mo after specimen collection.

AB - The Food and Drug Administration (FDA) has approved the Hybrid Capture® II (HC II) assay to test for the presence of high-risk types of human papilloma virus (HPV) DNA using specimens in PreservCyt® fixative for up to 21 days after collection. The ability of HC II to determine the presence of HPV DNA in actual patient samples after longer periods of storage has not been shown. To determine if specimens older than 21 days can yield useful results, 207 patient specimens that had been tested for HPV DNA by HC II (primary test) were tested again after a significant period of storage ranging from approximately 2.5 to 13.5 mo (retest). The results of the primary test and the retest agreed in 86% of the cases. The high level of agreement in the results suggests that the presence of high-risk types of HPV DNA can be determined from actual cervical cytology material in PreservCyt® with the HC II assay for at least 3 mo after specimen collection.

KW - Cervical cytology

KW - Human papilloma virus

KW - Hybrid Capture®

KW - Pap smear

KW - PreservCyt®

KW - Reproducibility

UR - http://www.scopus.com/inward/record.url?scp=17844401192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17844401192&partnerID=8YFLogxK

U2 - 10.1002/dc.20232

DO - 10.1002/dc.20232

M3 - Article

VL - 32

SP - 260

EP - 263

JO - Diagnostic Cytopathology

JF - Diagnostic Cytopathology

SN - 8755-1039

IS - 5

ER -